Introduction

Methods
Preparation of the molecular systems
A set of nine 3-amidinobenzyl-1H-indole-2-carboxamide inhibitors was selected (denoted by bold numbers according to the numbering in ref. 2) and they are shown in Figure 1 . Ligands 39, 57 and 63 have single positive charge, whereas the other six have a double positive charge. The simulations are based on the crystal structure of fXa in complex with 125. 2 The other eight inhibitors were manually built in the active site by replacing atoms or groups of the ligand 125. These binding modes were also independently confirmed by docking calculations using DOCK6. 30 The crystal structure of the fXa-125 complex shows two distinct conformations of the ligand with equal occupancy, caused by a 180 rotation of one of the amidinobenzyl groups. Therefore, both conformations were considered in this study and they will be referred to as A and B (Figure 2) .
The preparation of the receptor has been described previously: 23 All Asp and Glu residues were considered to have a negative charge and all the Arg and Lys residues were considered to have a positive charge. The histidine residues were protonated in the following way: Residues 57 and 83 were protonated on the N δ1 atom, residues 91, 145, and 199 on the N ε2 atom, and residue 13 on both atoms. This gave a net charge for the free protein of +2. No counter ions were added in the simulations. The protein was described by the Amber99 force field 31 and the inhibitors by the generalised Amber force field 32 with charges derived from a restrained electrostatic potential-procedure (RESP) 33 using ESP points calculated at the Hartree-Fock 6-31G* level and sampled with the Merz-Kollman scheme. 34 The protein-ligand complexes or the isolated ligands were immersed in a truncated octahedral box of TIP3P waters 35 that extended at least 10 Å from the solute.
Thermodynamic-integration calculations
Relative binding free energies were calculated using the thermodynamic cycle in Figure 3 . From this cycle, we can calculate the difference in binding free energy between ligand 1 (L1) and ligand 2 (L2) as
where  G bind is the binding free energy and  G L1 L2 is the free energy of mutating L1 into L2, either when they are bound to the receptor or when then they are free in solution.
The mutations considered are shown in Figure 1 . The  G L1 L2 energy differences are calculated using alchemical thermodynamic integration. Two variants of this approach were used. In the first, the process is divided into three transformations that we will call T1, T2, and T3. In T1, charges on atoms that change in the mutation are zeroed. In T2, the van der Waals parameters of the mutated atoms are changed, keeping the charges zeroed. Simultaneously, charges on the other atoms in the ligand are changed from those of L1 to those of L2 (in general, the RESP charges for the two ligands differ for all atoms, not only for the mutated atoms). Finally, in T3, L2 charges are introduced also on the mutated atoms. To avoid end-point problems in T2 (when atoms disappear), a soft-core version of the Lennard-Jones potential, as implemented in the Amber simulation package, was used. 36 This protocol using three transformations will be called the three-transformation approach (TTA) in the following.
A soft-core version of also the Coulomb potential was recently introduced in the Amber simulation package. This makes it possible to do both the charge and van der Waals mutations in the same step, and we will call this the single transformation-approach (STA).
To improve the convergence of the free-energy difference, the mutation of L1 to L2 was divided into several small steps, involving intermediate states, and total free energy of all transformations was calculated using
where the brackets indicate an average over snapshots from an MD trajectory and V is defined as V  = 1−V 0  V 1 where V 0 and V 1 is the potential energy of the L1 and L2 states, respectively. As a standard, nine  values were used (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.9), but we test different numbers of  values. Data for  = 0 and 1 were obtained by a linear interpolation using the two closest values. The integral in Eqn. 2 was estimated by the trapezoid method. In all calculations, we use a dual-topology scheme with two sets of coordinates for the atoms that differ between L1 and L2.
With such a scheme, we can actually also calculate the difference in binding free energies of the two conformations (A and B) for each ligand (in this case, we employ the same topology for the two states, but different coordinates for the atoms in the amidinobenzyl group as well as the joining CH 2 group). 37 We denote the free energy of changing the conformation of a ligand from the A to the B conformation ΔG conf . All TI calculations were performed with the Amber software, versions 10 38 (TTA) or 11 39 (STA).
MM/GBSA calculations
The MM/GBSA method estimates the binding free energy of a ligand, L, by 14, 15 
where PL denotes the complex and P is the protein. The brackets indicate averages over MD trajectories, and due to stability issues, 40 all the averages are taken from a simulation of the complex. Each free energy is calculated as the sum of five terms
which are the molecular-mechanics (MM) van der Waals energy, the electrostatic energy, the polar solvation free energy, the non-polar solvation free energy, and the absolute temperature multiplied by an entropy estimated at the MM level, respectively. The polar solvation energy, was estimated with the generalised Born method of Onufriev et al., model I, i.e., with α = 0.8, β = 0, and γ = 2.91. 41 The non-polar solvation energy was estimated from the solventaccessible surface area according to ∆G np = γSASA + b, where γ = 0.0227 kJ/mol/Å 2 and b = 3.85 kJ/mol. The entropy was estimated from harmonic frequencies, calculated at the MM level on a truncated and buffered system, as described previously, to improve the statistical precision of the estimate. 33 The other three terms were taken directly from the MD simulation, omitting the water molecules. All the terms in Eqn. 5 are averages over 40 snapshots taken from 40 independent MD simulations (i.e. in total 40  40 = 1600 energy estimates). 24 All MM/GBSA calculations were performed with the Amber 10 software.
Error estimates
All reported uncertainties are standard deviations of the mean (i.e. the standard deviation divided by the square root of the number of estimates). The standard error of the TI results was estimated in the following way: For each individual transformation and  value, the standard deviation of the mean of ∂V/∂ was calculated. Then, the standard deviation of the total   G bind estimate was obtained by error propagation (summing the variances, using the coefficients employed in the trapezoid formula). However, when several independent simulations were used to obtain the free energies (e.g. for  G conf ), the reported standard error is instead the standard deviation of the independent estimates divided by the square root of the number of independent calculations. This latter approach was also used for the MM/GBSA estimates: The reported standard error is the standard deviation of the mean over the 40 independent simulations (ignoring the standard deviation among the 40 snapshots in each simulation).
The performance of the free energy estimates was quantified by the mean unsigned error (MUE) from the experimental data, the correlation coefficient between the predicted and experimental data (r 2 ), and Pearlman's predictive index (PI). 42 These estimates are quite meaningless without an estimate of their uncertainty. The standard deviation of these quality measures was obtain by a simple simulation approach: 24 Each inhibitor was assigned a random number from a Gaussian distribution, with the mean and standard deviation of the mean obtained from the TI or MM/GBSA calculations. The quality measures (MUE, r 2 , and PI) were then calculated and the procedure was repeated 10 000 times. The standard error of these estimates is reported as the uncertainty.
MD simulations
All MD simulations were run using the sander module of Amber 10 38 or 11. 39 The temperature was kept constant at 300 K using a Langevin thermostat 43 with a collision frequency of 2.0 ps -1 , and the pressure was kept constant at 1 atm using a weak-coupling isotropic algorithm 44 with a relaxation time of 1 ps. Particle-mesh Ewald summation 45 with a fourth-order B spline interpolation and a tolerance of 10 -5 was used to handle long-range electrostatics. The cut-off for non-bonded interactions was set to 8 Å and the non-bonded pair list was updated every 50 fs. The SHAKE algorithm 46 was used to constrain bonds involving hydrogen atoms so that a 2 fs time step could be used.
The TI simulations were performed in the following way: The system at each λ value was minimized for 500 cycles of steepest descent, with all atoms except water molecules and hydrogen atoms restrained to their start position with a force constant of 418 kJ/mol/Å 2 . This was followed by a 20 ps constant-pressure simulation, using the same constraints, a 50 ps constant-pressure simulation without any restraints, and a 200 ps constant-volume simulation. Finally, a 2 ns production run was performed. The sampling frequency was determined by calculating the statistical inefficiency of the ∂V/∂ estimates. 47 These calculations suggested that the correlation time was between 5 and 10 ps in different simulations. Therefore, a sampling time of 10 ps was used throughout this investigation.
The MD simulations for the MM/GBSA estimates basically followed the solventinduced independent-trajectory (SIIT) approach recently suggested. 48 The 40 independent simulations were generated by solvating the protein-ligand complexes in different preequilibrated water boxes and using different random numbers for the initial velocities. The systems were then subjected to 500 cycles of steepest descent, with the same restraints as in the TI simulation, a 50 ps restrained constant-pressure simulation, followed by a 1 ns unrestrained constant-pressure simulations. Finally a 200 ps production run was performed and snapshots were saved every 5 ps. 24
Results and Discussion
Relative free energies estimated by TI
We have carried out free energy calculation on a set of nine fXa inhibitors using the theoretical rigorous thermodynamic integration (TI) approach and the simpler MM/GBSA method. This allow for a direct comparison of the methods. However, first we will develop an optimal TI protocol for this system.
The relative free energies of the eight mutations in Figure 1 , estimated by TI, are shown in Table 1 . For five of the mutations, the TI estimates are within 1 kJ/mol of the experimental value 2 at least for one of the four combinations tested, TTA or STA and conformations A or B. In fact, for the 53→9 and 53→47 mutations all four methods give errors of less than 2 kJ/mol, and the same is true for conformation A for mutations 125→53 and 53→50, whereas for mutation 53→59, only TTA with the B conformation gives an error of 1 kJ/mol and the other methods give errors of 3-4 kJ/mol. These mutations also give a good precision of 0.6-0.8 kJ/mol for TTA and 0.3-0.7 kJ/mol for STA.
On the other hand, for three mutations, 63→39, 53→57, and 50→63, the errors are instead 8-14 kJ/mol for all methods. All these mutations involve the amidinobenzyl group and they also involve all ligands with a single positive charge (i.e. mutations 53→57 and 50→63 involve a change of the net charge of the ligand, which has turned out to be problematic in previous TI studies 49 ). The 63→39 mutation, on the other hand involves a H→OCH 3 mutation, i.e., the formation of a rather large group. However, similar large mutations have been carried out with higher accuracy previously. 50 The standard error for the free-energy estimates for the charge mutations is 1.4-1.7 kJ/mol, i.e. twice as large as for the five wellbehaving mutations. Again STA gives a slightly better precision. The 63→39 mutation gives an intermediate precision of ~1 kJ/mol and the increased uncertainty comes mainly from the van der Waals perturbation (T2).
Simulation based on the two binding conformations (A and B) resulted in rather similar estimates for most of the mutations with differences of 0-6 kJ/mol. The largest differences are observed for the 53→50 and the 53→57 mutations. Neither of the two conformations gives consistently better results than the other.
Additional tests on some mutations
In an attempt to understand why three of the mutations give large errors compared to experiments, additional TI simulations based on the A conformation were carried out for these mutations.
For the 63→39 mutation, we performed three additional tests. First, we changed the TTA transformation scheme slightly: In the original scheme, T2 involves not only the van der Waals transformation, but also transformation of charges on atoms that are common to both ligands. If the van der Waals transformation is rather large, T2 may converge faster if we move all the charge transformations to T1 and T3 (i.e. if all charges in the ligand are zeroed in T1 and they are restored to those of ligand 39 in T3) and do only the van der Waals transformation in T2. Using this new scheme (which we call TTA' in the following), the estimated free energy was 0.4±3.0 kJ/mol. Thus, the error decreased from 12 to 10 kJ/mol, but the uncertainty increased by a factor of 2.5, so the change is not statistically significant. The larger uncertainty stems mainly from T1 and T3, because larger transformations are carried out. Therefore, ten independent MD simulations were carried out at each λ value. The use of independent trajectories has been shown to improve TI estimates for large mutations. 51 This resulted in an estimate of 0.4±4.9 kJ/mol, showing that the error estimate from error propagation underestimates the true uncertainty of the calculations. To improve the integration, more λ values were added at places where the curvature of the ∂V/∂ curve was high, but this did not result in any statistically significant change. Finally, ten independent TI calculations were carried out also with the original TTA decomposition and this resulted in an estimate of -3.5±1.2 kJ/mol, i.e. still no significant change.
For the 53→57 and 50→63 mutations, the alternative TTA' decomposition was also tested. The results were 11.0±2.5 kJ/mol and 20.7±2.7 kJ/mol, which are not significantly different from the original results. Further tests were carried out, but only on the first T1 transformation in the original TTA scheme, i.e. the removal of charges on atoms unique to ligands 53 and 50, respectively. The number of λ values was increased to 19, the time step was reduced to 1 fs, the box size was doubled, the equilibration time was increased to 2.2 ns, and the production time was increased to 4 ns. The results of these tests are collected in Table  2 . The only test that resulted in a significant improvement was the doubling of the box size for the 50→63 mutation. However, it is unclear if this is a general way to improve the results, because it did not lead to any significant improvement for the 53→57 mutation. However, the results show that these TI results are not fully converged with the standard protocol. In particular, it can be seen from Figure S1 (in the supplementary material) that the proteinligand simulations require more than 2 ns to converge within 1 kJ/mol, whereas the freeligand simulations are converged already after 1 ns.
Altogether, these test indicate that the poor results of the 63→39, 53→57, and 50→63, mutations are not caused by convergence problems or limitations in the TI protocol used. Considering that all three mutations involve the same amidinobenzyl group, it is possible that the reason for the poor results is that these three ligands bind in a mode different from that observed in the crystal structure of ligand 125. This is also supported by the fact that the two initial mutations of this group give a too positive energy difference, indicating that the final binding mode of ligands 57 and 63 is too unfavourable. We have tried to identify alternative binding modes for these ligands by MD simulations and docking, but we have not found any reasonable alternatives. Another possibility is that this amidinobenzyl group interacts with the surrounding protein through cation- interactions with Trp and Phe groups and that this interaction is poorly described by the non-polarisable Amber force field. 52 
Free energy difference between A and B conformation
As mentioned in the Methods section, we also used TI to calculate the free energy difference of the binding energy for each ligand between conformations A and B,  G conf . The results are shown in Table 3 . All the free energy estimates were obtained from five independent simulations at each λ value. This was necessary in order to obtain a smooth curve for the integration, owing to the quite large changes during the transformations.
Starting with the TTA results, four of the ligands show a preference for the B conformation and the other five show a preference for the A conformation (by 0-6 kJ/mol). However, the uncertainties are so large for these estimates (2-3 kJ/mol), even though an independent-trajectory approach was used, so that none of the estimated  G conf values is significantly different from 0 kJ/mol at the 95% confidence level. For ligand 125, this is in line with the crystallographic data, which show equal occupancy of the two binding conformations. For the other ligands, these results indicate that the cleft where this part of the ligand binds is sufficiently large to accommodate two binding modes (see Figure 2 ).
The STA results predicts a preference for the B conformation for all ligands (by 1-11 kJ/ml), but again, none of the  G conf estimates are significantly different from 0 kJ/mol. For seven of the ligands, the uncertainty is larger with the STA approach, compared to the TTA approach. This indicates that STA could have problems with larger mutations. On the other hand, only ligand 53 gives a significant difference between STA and TTA at the 95% confidence level.
Number of integration points
Considering that the results in Table 2 show no significant changes in the free energy when the number of integration points (λ values) is increased, it would be of interest to instead decrease the number of integration points, in order to decrease the computational expense. The free energy of charge transformations is usually assumed to follow the linear response approximation (LRA), according to which only two integration points are necessary to compute the free energy, viz. the end-points. We therefore calculated the difference  G bound −  G free with only two λ values and compared the results with the estimates using all nine λ values using TTA. The results can be seen in Table 4 and most of the T1 and T3 transformations work well with only two λ values (0.1 and 0.9), with a mean absolute deviation (MAD) of less than 1 kJ/mol. However, three of the mutations showed larger differences, up to 3 kJ/mol. Moreover, the T2 transformation, which is mainly a van der Waals transformation, performed much worse, with a MAD of 2 kJ/mol and a maximum difference of 4 kJ/mol.
The use of two λ values implies a linear relation. Therefore, we also tested a single λ value (0.5). The results in Table 4 indicate that this extensive simplification gives slightly worse results than with two λ values, with MADs of 1 kJ/mol for T1 and T3, but 2 kJ/mol for T2, and with maximum deviations of up to 3 kJ/mol for T1 and 7 kJ/mol for T2.
Next, we computed the difference  G bound −  G free with three (0.1, 0.5, and 0.9) and five (0.1, 0.3, 0.5, 0.7, and 0.9) λ values as well. These results are also shown in Table 4 . It can be seen that at least five λ values are required if we aim at a MAD of less than 1 kJ/mol also for T2. The maximum difference is then less than 2 kJ/mol, which is actually similar to the standard error. Therefore, we tested two λ values for T1 and T3 and five λ values for T2, which will be denoted 2/5/2.
The difference in the total calculated binding free energies using 9 or 2/5/2 λ values are listed in Table 5 . It can be seen that for four of the mutations, the difference is less than 1 kJ/mol, i.e. similar to the standard error. However, for the other four mutations, the deviation is larger, up to 6 kJ/mol. Still, the difference is statistically significant only for one of the sixteen mutations at the 95% level, viz., the 53→49 mutation in the B conformation. This deviation comes mainly from T3, which shows a deviation of -5.3 kJ/mol. This deviation is decreased to -1.2 kJ/mol if instead 3 λ values are used for T3. This indicates that it is safer to use 3/5/3 λ values instead. The results using such an approach are shown in Table 5 as well. It gives MADs and maximum deviations of less than 1 kJ/mol and 2-3 kJ/mol, respectively, which is more satisfying than the 2/5/2 results. The MUE of this approach compared to the experimental binding energies is slightly smaller than with nine λ values, but the difference is not significant.
Likewise, we also investigated how many λ values are necessary with STA. The results with one, two, three, and five λ values are compared with those with nine λ values in Table 4 . It is clear that two λ values is not sufficient, giving a MAD of 2 kJ/mol and a maximum deviation of 8 kJ/mol. However, three λ values, seems to work surprisingly well with a MAD of less than 1 kJ/mol and a maximum difference of less than 3 kJ/mol. With five λ values, the MAD is 0.4 kJ/mol and the maximum deviation is 1 kJ/mol. Using three λ values, the calculated total binding free energies are shown in Table 5 . It can be seen that that the MAD to the calculations with nine λ values is well below 1 kJ/mol, with maximum differences of 1-3 kJ/mol. In particular, none of the mutations gave any statistically significant difference. Compared to the experimental results, such an approach gives slightly larger errors (MUE = 6 kJ/mol) than with nine λ values, but the difference is not significant.
Simulation length
To further decrease the computational cost, the simulation length might be decreased. This is especially pertinent to the protein-ligand simulations, because these have approximately five times larger CPU requirements than the free-ligand simulations. Therefore, we calculated   G bind using 9 λ values, as a function of the protein-ligand simulation length for TTA. The results are plotted in Figure 4 . If an error of 1 kJ/mol is accepted, all but the two simulations involving a change in the charge of the ligand have converged after 1 ns simulation. On the other hand, the charge mutations 53→ 57, and 50→63 require 2.3-2.6 ns simulations to converge, as was discussed above ( Figure S1 ). Thus, we can conclude that for mutations that do not involve a change of the total charge, the protein-ligand simulation length can be halved.
The next step is then to fix the protein-ligand simulation length at 1 ns, and evaluate   G bind as a function of the length of the free-ligand simulation. This is shown in Figure  5 . In this cases, the mutations 63→39, 50→63, and 125→53 show the slowest convergence, although the fluctuations are much smaller. If again an error of 1 kJ/mol is allowed, a 1.1 ns free-ligand simulation is needed.
If we repeat these evaluations, but using 3/5/3 λ values, the results are more or less the same as with using all the nine λ values ( Figures S2 and S3 ), except that some of the freeligand simulations show a slower convergence, up to 1.7 ns. Therefore, considering the relatively small gain of deceasing this simulation time from 2 to 1.1 ns, we suggest that a 2 ns free-ligand simulation is still motivated (and 1 ns for the protein-ligand simulations, unless the charge is changed). The results of such calculations are shown in Table 6 . The MAD is 1 kJ/mol and the maximum deviation from the original approach is 5-6 kJ/mol. Only one of the charge mutations shows statistically significant changes. The standard errors of the   G bind estimates are also shown in Table 6 and it can be seen that the precision is only slightly worse with this optimized protocol, 1 kJ/mol for the five well-behaving mutations, 2 kJ/mol for the two charge mutations, and ~1.5 kJ/mol for the 63→39 mutation. The MUE is not significantly different from the original results, 5 kJ/mol for the A conformation and 6 kJ/mol for the B conformation.
The same evaluation was repeated also for the STA. In Figures S4 and S5 ,   G bind is plotted as a function of the length of the protein-ligand and free-ligand simulations, respectively. The results show that the former simulations are converged after 1 ns for all mutations, except the 50 → 63 charge mutation. Thus, the analysis showed that STA has the same equilibration properties as TTA. The results are similar when using only three integration points, as is shown in Figures S6 and S7 . This implies that for most of the mutations, it is sufficient to use three λ values, 1 ns protein-ligand simulation time, and 2 ns free-ligand simulation time with STA. Again, the exceptions are mutations that involves a change of net charge. The results using such a protocol are collected in Table 6 . It can be seen that it gives MADs of 1 kJ/mol and maximum deviations from the original scheme of 4-6 kJ/mol, although none of the differences are statistically significant. The precision is nearly identical to that of the TTA (3/5/3) protocol. The MUE compared to the experimental data is identical for the B conformation, but slightly larger for the A conformation (7 kJ/mol).
MM/GBSA estimates MM/GBSA is a simpler method than TI, based on only end-point simulations of the proteinligand complex. Therefore, it is interesting to compare the results of the two methods. In fact, MM/GBSA predicts absolute binding affinities. The absolute estimates for the binding of our nine fXa ligands are shown in Table 7 . The MUEtr (the MUE when the mean signed error, -17 and -13 kJ/mol for conformation A and B, respectively, has been subtracted from each estimate) of 3-4 kJ/mol is impressive for this kind of calculation. However, it should be noted that the null-hypothesis that all the ligands have the same affinity gives a MUEtr of only 5 kJ/mol, so this good result mainly reflects the rather small range of binding affinities studied (20 kJ/mol). On the other hand, the predictive index (PI) of the MM/GBSA estimates is 0.8, which shows that the ranking of the inhibitors is quite good, whereas the correlation coefficients of 0.7 and 0.5 are more mediocre.
Therefore, it would be interesting to compare the free energy differences for the eight considered mutations obtained with TI and MM/GBSA. The latter are also shown in Table 6 . Interestingly, the MUEs of the MM/GBSA estimates, 4-5 kJ/mol, are actually somewhat lower than TI. This success of MM/GBSA can be attributed to the fact that it gives better results for the mutations involving a change of net charge (53→ 57 and 50→63) , with errors of up to 6 kJ/mol. Instead, the largest error is found for the 63→ 39 perturbation (7-10 kJ/mol). On the other hand, the TI method gives a better correlation to the experimental results than MM/GBSA (r 2 = 0.3, compared to 0.2), although both correlations are quite poor. Likewise, MM/GBSA predicts the wrong sign of   G bind for 3-4 of the eight mutations, whereas TI predicts the wrong sign for 2-3 of them.
The MM/GBSA calculations may also give some insight into the relative stability of the A and B conformations, because these estimates are based upon physically well-defined terms. The various energy terms for this difference are shown in Table 8 . The electrostatic contribution (ΔE ele + ΔG solv ) is small (< 2 kJ/mol) for most inhibitors, except for the ligands 49 and 57 (7 and 3 kJ/mol). The largest differences are instead found for the non-electrostatic part (up to 11 kJ/mol), which is typically dominated by the van der Waals term, although it is somewhat compensated by the entropy, i.e. an enthalpy-entropy compensation. It is interesting to note that MM/GBSA predicts that the A conformation is preferred for all of the ligands, contrary to TI (especially STA), which showed a slight preference for the B conformation. However, only one (TTA) or two (STA) of the differences are statistically significant at the 95% level.
The results MM/GBSA often depends strongly on the continuum-solvation method employed. 53 Therefore, we also tested the Poisson-Boltzmann solvation model, implemented in Amber 11. As can be seen in Table S1 in the supplementary material, such a MM/PBSA approach gave binding affinities that were 45 kJ/mol more positive on average than the corresponding MM/GBSA estimates. Unfortunately, these estimates reproduce the experimental results poorly, both in absolute and relative terms: In particular, both the correlation coefficient (r) and the PI are negative, indicating an anticorrelation for the absolute affinities. Likewise, the correlation coefficient is negative for the relative affinities. This shows that for this test case, there is no gain of using the more fundamental PB method than the GB method for continuum-solvation energies.
Finally, we also tested to calculate the affinities with a simple docking method, viz. AutoDock, 54 using default parameters and the AutoDock score function. 55 The protein was considered rigid in all docking calculations whereas the ligands were fully flexible. The results of these calculations are also included in Table S1 in the supplementary material. It can be seen that AutoDock also performed poor on this system: Both the correlation coefficient and the PI are negative for the absolute affinities. Likewise, the correlation coefficient is essentially zero for the relative affinities (r 2 = 0.02) and the MUE, 6 kJ/mol, is larger than for the null-hypothesis Timings When comparing the TI and MM/GBSA approaches, the time consumption of the two methods is of course also of interest. A 1-ns MD simulation of the protein-ligand complex takes ~34 CPU hours on a 2.27 GHz Intel Xeon machine, whereas the free-ligand simulations take only ~7 CPU hours. Moreover, the TI dual-topology implementation in Amber requires a minimum of 2 CPUs. From this we can estimate the total amount of CPU time required for the various protocols. These estimates are shown in Table 9 . The original TTA protocol requires in total ~4800 CPU hours, whereas the original STA protocol requires only ~1600 CPU hours. This is a huge amount, about 7 and 2 weeks, respectively, which is too expensive to use on a regular basis. If we instead use our optimised approach with a reduced number of integration points (3/5/3) and simulation lengths, the TTA approach takes ~1200 CPU hours, a 4-fold reduction. Likewise, the time-consumption for STA can be reduced by a factor of ~5 to 337 CPU hours. Moreover, the TI calculations can be trivially parallelised, by running the MD simulations at each integration point concurrently. Using such an approach, both TTA and STA take only ~40 CPU hours in the best scenario, but they then require at least 27 and 15 processors, respectively (two 2.2-ns free-ligand simulations can be run at the same time of one 1.2-ns protein-ligand complex simulation).
Surprisingly, the MM/GBSA estimates take ~1600 CPU hours, which is actually longer than for the optimised TI approaches. The reason for this is that the inherent precision is better for TI, because it calculates only relative energies, whereas MM/GBSA always calculates absolute binding energies. Therefore, MM/GBSA requires a large number of independent simulations (40) to obtain a precision of 1 kJ/mol. Of course, the time consumption of MM/GBSA can be strongly reduced if a lower precision is tolerated (e.g. by a factor of 4 for a precision of 2 kJ/mol), but the same applies to TI and it is quite meaningless to compare methods that do not give a similar precision (the precision of the MM/GBSA estimates are already slightly worse than that of TI). Moreover, fXa requires a long equilibration time with the SIIT approach. A gain in total CPU time could be obtained if the velocity-induced independent trajectories (VIIT) approach was instead used to generate the independent simulations, 48 because this would allow the long equilibration (1 ns) to be run only once (total CPU time ~540 h, i.e. still longer than for the optimised STA approach). To this we should add a few hours of post-processing, (TI requires only a couple of minutes for the integration). On the other hand, MM/GBSA could gain from using the pmemd module in Amber, which is significantly faster (by a factor of ~2) than the standard sander module, especially in parallel runs, but it cannot be used for TI. If all calculations could be run concurrently, the MM/GBSA SIIT approach would require 40 CPU h on 40 nodes. The 40 bulk calculations with the VIIT approach would take only 17 CPU h, but a single 1 ns equilibration (34 h) would probably still be required.
Conclusions
We have calculated binding free-energy differences for eight pairs of fXa 3-amidinobenzyl-1H-indole-2-carboxamide inhibitors with the TI and MM/GBSA methods. This turned out to be quite difficult, because the ligands can bind in two distinct conformations. Therefore, we estimated the free energy of mutating conformation A to B for each ligand bound to the protein. Unfortunately, these mutations are hard to converge, but the results indicate that neither conformation is significantly preferred over the other, in accordance with the crystal structure showing equal occupancy for the two conformations of ligand 125. 2 With a standard TI protocol, we could estimate the difference in binding free energy of five pairs of ligands with a precision better than 1 kJ/mol and with a MUE of 2 kJ/mol. The STA protocol (with a single transformation at each λ value), gave a slightly better precision and it is appreciably faster and simpler . For two mutations that involved a change of the net charge of the ligand, the statistical uncertainty was twice as large and the errors 7-14 kJ/mol. For the last mutation (63→39), the precision was intermediate, but the error was still large. This may indicate that ligands with neutralising mutations in the amidinobenzyl group binds in a different mode.
Encouragingly, we have shown that for most of the mutations, the TI protocol can be tuned to decrease the computational demand while still retaining the accuracy and precision. If all simulations at each λ values can be run concurrently, one could obtain an TI estimate of ΔG bind within ~2 days (on 15-27 CPUs) and both the TTA and STA approaches take a same amount of time, whereas STA is better if one has more limited computer resources.
Quite unexpectedly, we found that the more approximate MM/GBSA method gives overall estimates that are somewhat better than the TI results. However, this is mainly owing to that MM/GBSA performs better for the mutations that involve a change of the net charge. Interestingly, in its current implementation, the MM/GBSA method has a larger total computational demand than TI, if a similar precision is required for both methods.
In conclusion, our results indicate that TI could be a useful tool in drug design with a carefully design the simulations, if all ligands involve a common scaffold. Mutations that change the charge should be avoided, because they are prone give to large errors and are much harder to converge. Without such mutations, we have shown that a precision better than 1 kJ/mol and a average accuracy of 2 kJ/mol could be obtained at a cost of ~340 CPU h per ligand. Table 3 . Free energy difference between the two binding conformations of each ligand (  G conf ; kJ/mol).
Ligand
TTA STA T1  T2  T3  STA   # λ values  1  2 3  5  1  2  3  5  1  2  3  5  1 2 The table reports differences relative to the results obtained with nine λ values. A positive difference indicates that the estimate with nine λ values is more positive. The number of λ values used is indicated in the parenthesis. * marks deviations that are statistically significant at the 95% level. MAD and Max are the mean absolute deviation and maximum deviation from the estimate with nine λ values. MUE is the mean unsigned error compared to the experimental data. The length of the production simulation was 1 ns for the protein-ligand simulation and 2 ns for the free-ligand simulations. The number of λ values is shown in parenthesis. ** marks deviations from a protein-ligand simulation length of 2 ns that are statistically significant at the 99% level. Figure 1 -The nine fXa inhibitors considered in this study. The mutations explicitly modelled in the TI calculations are shown with arrows, and the groups introduced in each mutation are shown in bold.
Figure 2 -
The two conformations of ligand 125 in the crystal structure. 2 The A conformation is shown in cyan and the B conformation is shown in green (without nonpolar hydrogen atoms). Figure 3 -The thermodynamic cycle used to compute the free energy differences.
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P+L1 PL1
P+L2 PL2
G bind L1 G bind L2 G free L1  L2 G bound L1  L2 Figure 4 -The dependence of ΔΔG bind on the protein-ligand simulation length for the TTA approach. The free energies shown are deviations relative to a simulation time of 2 ns. Figure 5 -The dependence of ΔΔG bind on the freeligand simulation length with the TTA approach. The free energies shown are deviations relative to a simulation time of 2 ns. The protein-ligand simulation time was fixed at 1 ns.
